<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Revive Therapeutics Ltd — News on 6ix</title>
<link>https://6ix.com/company/revive-therapeutics-ltd</link>
<description>Latest news and press releases for Revive Therapeutics Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 15 Dec 2025 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/revive-therapeutics-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683683b178dffbe2df16961b.webp</url>
<title>Revive Therapeutics Ltd</title>
<link>https://6ix.com/company/revive-therapeutics-ltd</link>
</image>
<item>
<title>Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-provides-key-nerve-123000738</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-provides-key-nerve-123000738</guid>
<pubDate>Mon, 15 Dec 2025 12:30:00 GMT</pubDate>
<description>TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&D Canada – Suffield Resear</description>
</item>
<item>
<title>Revive Therapeutics Announces Closing of Second Tranche of Private Placement</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-closing-second-210000983</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-closing-second-210000983</guid>
<pubDate>Fri, 19 Sep 2025 21:00:00 GMT</pubDate>
<description>TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400. Each unit is com</description>
</item>
<item>
<title>Revive Therapeutics Announces Extension of Proposed Private Placement</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-extension-proposed-235000680</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-extension-proposed-235000680</guid>
<pubDate>Fri, 05 Sep 2025 23:50:00 GMT</pubDate>
<description>TORONTO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is extending is previously announced private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000. Revive closed a first tranche of the private placement in ear</description>
</item>
<item>
<title>Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-closing-first-232800037</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-closing-first-232800037</guid>
<pubDate>Mon, 11 Aug 2025 23:28:00 GMT</pubDate>
<description>TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.0</description>
</item>
<item>
<title>Revive Therapeutics Announces Proposed Private Placement and Debt Settlement</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-proposed-private-002100881</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-proposed-private-002100881</guid>
<pubDate>Thu, 31 Jul 2025 00:21:00 GMT</pubDate>
<description>TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing to arrange a private placement offering of up to 30,952,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of up to $650,000, and to settle $67,400 owing pursuant to an arm’s length note payable by t</description>
</item>
<item>
<title>Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-clarifies-completion-key-211000865</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-clarifies-completion-key-211000865</guid>
<pubDate>Tue, 08 Jul 2025 21:10:00 GMT</pubDate>
<description>TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Re</description>
</item>
<item>
<title>Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-nears-completion-key-110000731</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-nears-completion-key-110000731</guid>
<pubDate>Thu, 26 Jun 2025 11:00:00 GMT</pubDate>
<description>TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC</description>
</item>
<item>
<title>Revive Therapeutics Advances with Next-Generation Bucillamine Development</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-advances-next-generation-105500285</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-advances-next-generation-105500285</guid>
<pubDate>Wed, 04 Jun 2025 10:55:00 GMT</pubDate>
<description>TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, is pleased to announce the advancement of its next-generation lyophilized formulation of Bucillamine (“New Bucillamine”). Developed in collaboration with the esteemed University of Waterloo, this breakthrough aims to address significant unmet medical</description>
</item>
<item>
<title>Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-provides-research-study-180700649</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-provides-research-study-180700649</guid>
<pubDate>Mon, 12 May 2025 18:07:00 GMT</pubDate>
<description>TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”</description>
</item>
<item>
<title>Revive Therapeutics Announces Proposed Shares for Debt Transaction</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-proposed-shares-203000269</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-proposed-shares-203000269</guid>
<pubDate>Mon, 21 Apr 2025 20:30:00 GMT</pubDate>
<description>TORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announces that it is proposing to settle an aggregate of $150,000 in payables to arm’s length parties through the issuance of up to 6,000,000 common shares, at a proposed issue price of $0.025 per sha</description>
</item>
<item>
<title>Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-investigate-bucillamine-potential-110000843</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-investigate-bucillamine-potential-110000843</guid>
<pubDate>Thu, 10 Apr 2025 11:00:00 GMT</pubDate>
<description>TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announced today that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute. The researcher aims to investigate Bucillamine’s potential as a cancer treatment,</description>
</item>
<item>
<title>Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-acquisition-molecular-113000605</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-acquisition-molecular-113000605</guid>
<pubDate>Tue, 01 Apr 2025 11:30:00 GMT</pubDate>
<description>TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it has entered into an asset purchase agreement (the “Agreement”) dated March 31, 2025 with DiagnaMed Holdings Corp. (CSE:</description>
</item>
<item>
<title>Revive Therapeutics Announces Results of Annual Shareholder Meeting</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-results-annual-131400103</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-results-annual-131400103</guid>
<pubDate>Wed, 19 Mar 2025 13:14:00 GMT</pubDate>
<description>TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025. At the Meeting, shareholders elected the followin</description>
</item>
<item>
<title>Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-loi-acquire-130000963</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-announces-loi-acquire-130000963</guid>
<pubDate>Mon, 03 Mar 2025 13:00:00 GMT</pubDate>
<description>TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025, to acquire the full rights to DiagnaMed Holdings Corp.’s (CSE: DMED) (OTCQB: DGNMF)</description>
</item>
<item>
<title>Revive Therapeutics Prices and Files Final Prospectus for Equity Financing</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-prices-and-files-final-prospectus-for-equity-financing</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/revive-therapeutics-prices-and-files-final-prospectus-for-equity-financing</guid>
<pubDate>Fri, 05 Dec 2014 17:01:00 GMT</pubDate>
<description>/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN&#xA0; CANADA &#xA0;AND IS NOT AUTHORIZE...</description>
</item>
<item>
<title>IIROC Trade Halt - Mercury Capital II Limited</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/iiroc-trade-halt-mercury-capital-ii-limited</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/iiroc-trade-halt-mercury-capital-ii-limited</guid>
<pubDate>Thu, 18 Jul 2013 17:48:14 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - July 18, 2013) - The following issues have been...</description>
</item>
<item>
<title>IIROC Trading Halt - MFF.P</title>
<link>https://6ix.com/company/revive-therapeutics-ltd/news/iiroc-trading-halt-mffp</link>
<guid isPermaLink="true">https://6ix.com/company/revive-therapeutics-ltd/news/iiroc-trading-halt-mffp</guid>
<pubDate>Thu, 18 Jul 2013 17:47:00 GMT</pubDate>
<description>VANCOUVER , July 18, 2013 /CNW/ - The following issues have been halted by IIROC: Co...</description>
</item>
</channel>
</rss>